← Back to all trials
Not Yet Recruiting
NCT05739292
Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old
Conditions: Infection, Meningococcal
Sex: All
Ages: 19 Years – 55 Years
Healthy volunteers: 1
Phase: PHASE1
Enrollment: 60
Sponsor: EuBiologics Co.,Ltd
Location: Korea, Republic of
Summary
Phase I study to evaluate safety and immunogenicity in healthy adult subjects following a single dose administration of Meningococcal (Group A, C, W-135, X, and Y)-CRM197 Conjugate vaccine
Eligibility Criteria
Inclusion Criteria:Subjects 19 to 55 years of ageWritten informed consentAvailable for all visits and telephone calls scheduled for the studyExclusion Criteria:Previous or suspected disease caused by N. meningitidisHousehold and/or intimate exposure to an individual with culture-proven N. meinigitidis infection within 60 days prior to screeningSerious acute, chronic or progressive disease as determined by investigatorHistory of alcohol or substance abuse
Source: ClinicalTrials.gov (NCT05739292). StuddyBuddy aggregates publicly available trial information.
